These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 27923066)

  • 21. Comprehensive molecular profiling of lung adenocarcinoma.
    Cancer Genome Atlas Research Network
    Nature; 2014 Jul; 511(7511):543-50. PubMed ID: 25079552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of somatic alterations in stage I lung adenocarcinomas by next-generation sequencing.
    Zhao Y; Yang J; Chen Z; Gao Z; Zhou F; Li X; Li J; Shi S; Feng X; Sun N; Yao R; Zhou C; Chang S; Li M; Zhou Y; Li L; Zhang X; He J
    Genes Chromosomes Cancer; 2014 Apr; 53(4):289-98. PubMed ID: 24449147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma.
    Xiang C; Ji C; Cai Y; Teng H; Wang Y; Zhao R; Shang Z; Guo L; Chen S; Lizaso A; Lin J; Wang H; Li B; Zhang Z; Zhao J; Wei J; Liu J; Zhu L; Fang W; Han Y
    Mod Pathol; 2022 Sep; 35(9):1181-1192. PubMed ID: 35641658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
    Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
    Mol Cancer; 2019 Jan; 18(1):7. PubMed ID: 30626401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis.
    O'Farrell H; Harbourne B; Kurlawala Z; Inoue Y; Nagelberg AL; Martinez VD; Lu D; Oh MH; Coe BP; Thu KL; Somwar R; Lam S; Lam WL; Unni AM; Beverly L; Lockwood WW
    J Thorac Oncol; 2019 Apr; 14(4):656-671. PubMed ID: 30578931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.
    Hintzsche J; Kim J; Yadav V; Amato C; Robinson SE; Seelenfreund E; Shellman Y; Wisell J; Applegate A; McCarter M; Box N; Tentler J; De S; Robinson WA; Tan AC
    J Am Med Inform Assoc; 2016 Jul; 23(4):721-30. PubMed ID: 27026619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
    Caso R; Sanchez-Vega F; Tan KS; Mastrogiacomo B; Zhou J; Jones GD; Nguyen B; Schultz N; Connolly JG; Brandt WS; Bott MJ; Rocco G; Molena D; Isbell JM; Liu Y; Mayo MW; Adusumilli PS; Travis WD; Jones DR
    J Thorac Oncol; 2020 Dec; 15(12):1844-1856. PubMed ID: 32791233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exome-wide Sequencing Shows Low Mutation Rates and Identifies Novel Mutated Genes in Seminomas.
    Cutcutache I; Suzuki Y; Tan IB; Ramgopal S; Zhang S; Ramnarayanan K; Gan A; Lee HH; Tay ST; Ooi A; Ong CK; Bolthouse JT; Lane BR; Anema JG; Kahnoski RJ; Tan P; Teh BT; Rozen SG
    Eur Urol; 2015 Jul; 68(1):77-83. PubMed ID: 25597018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A detrimental mutation on USP40 unlocks the tumorigenesis in a rare case of lung cancer.
    Xu ZH; Wang H; Ji XY; Zhang FX; Gao BL; Hu JA; Zheng J
    Int J Clin Exp Pathol; 2019; 12(3):740-749. PubMed ID: 31933881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymph node metastasis in early invasive lung adenocarcinoma: Prediction model establishment and validation based on genomic profiling and clinicopathologic characteristics.
    Guo W; Lu T; Song Y; Li A; Feng X; Han D; Cao Y; Sun D; Gong X; Li C; Jin R; Du H; Chen K; Xiang J; Hang J; Chen G; Li H
    Cancer Med; 2024 Jul; 13(14):e70039. PubMed ID: 39046176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptomic heterogeneity of driver gene mutations reveals novel mutual exclusivity and improves exploration of functional associations.
    Lan Y; Liu W; Zhang W; Hu J; Zhu X; Wan L; A S; Ping Y; Xiao Y
    Cancer Med; 2021 Jul; 10(14):4977-4993. PubMed ID: 34076361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.
    Arcila ME; Drilon A; Sylvester BE; Lovly CM; Borsu L; Reva B; Kris MG; Solit DB; Ladanyi M
    Clin Cancer Res; 2015 Apr; 21(8):1935-43. PubMed ID: 25351745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrative analysis of genomic sequencing data reveals higher prevalence of LRP1B mutations in lung adenocarcinoma patients with COPD.
    Xiao D; Li F; Pan H; Liang H; Wu K; He J
    Sci Rep; 2017 May; 7(1):2121. PubMed ID: 28522810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.
    Wilkerson MD; Yin X; Walter V; Zhao N; Cabanski CR; Hayward MC; Miller CR; Socinski MA; Parsons AM; Thorne LB; Haithcock BE; Veeramachaneni NK; Funkhouser WK; Randell SH; Bernard PS; Perou CM; Hayes DN
    PLoS One; 2012; 7(5):e36530. PubMed ID: 22590557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
    Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
    Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq.
    Zhang L; Li S; Choi YL; Lee J; Gong Z; Liu X; Pei Y; Jiang A; Ye M; Mao M; Zhang X; Kim J; Chen R
    Lung Cancer; 2017 Jul; 109():21-27. PubMed ID: 28577945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole exome sequencing and MicroRNA profiling of lung adenocarcinoma identified risk prediction features for tumors at stage I and its substages.
    Ho H; Yu SL; Chen HY; Yuan SS; Su KY; Hsu YC; Hsu CP; Chuang CY; Chang YH; Li YC; Cheng CL; Chang GC; Yang PC; Li KC
    Lung Cancer; 2023 Oct; 184():107352. PubMed ID: 37657238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors.
    Wen Y; Lin A; Zhu W; Wei T; Luo P; Guo L; Zhang J
    Front Pharmacol; 2021; 12():645862. PubMed ID: 34163353
    [No Abstract]   [Full Text] [Related]  

  • 39. Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma.
    Choi S; Kim HR; Sung CO; Kim J; Kim S; Ahn SM; Choi CM; Chun SM; Choi EK; Kim SW; Kim YH; Lee JY; Song JS; Kim D; Haq F; Lee SY; Lee JE; Jung WR; Jang HY; Yang E; Lee C; Yu E; Kong G; Baek D; Jang SJ
    Clin Cancer Res; 2015 Jun; 21(11):2613-23. PubMed ID: 25294902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer.
    Kadara H; Sivakumar S; Jakubek Y; San Lucas FA; Lang W; McDowell T; Weber Z; Behrens C; Davies GE; Kalhor N; Moran C; El-Zein R; Mehran R; Swisher SG; Wang J; Zhang J; Fujimoto J; Fowler J; Heymach JV; Dubinett S; Spira AE; Ehli EA; Wistuba II; Scheet P
    Am J Respir Crit Care Med; 2019 Sep; 200(6):742-750. PubMed ID: 30896962
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.